TY - JOUR
T1 - TGF-β Receptor Inhibitors Target the CD44 high /Id1 high Glioma-Initiating Cell Population in Human Glioblastoma
AU - Anido, Judit
AU - Sáez-Borderías, Andrea
AU - Gonzàlez-Juncà, Alba
AU - Rodón, Laura
AU - Folch, Gerard
AU - Carmona, Maria A.
AU - Prieto-Sánchez, Rosa M.
AU - Barba, Ignasi
AU - Martínez-Sáez, Elena
AU - Prudkin, Ludmila
AU - Cuartas, Isabel
AU - Raventós, Carolina
AU - Martínez-Ricarte, Francisco
AU - Poca, M. Antonia
AU - García-Dorado, David
AU - Lahn, Michael M.
AU - Yingling, Jonathan M.
AU - Rodón, Jordi
AU - Sahuquillo, Juan
AU - Baselga, José
AU - Seoane, Joan
PY - 2010/12/14
Y1 - 2010/12/14
N2 - Glioma-initiating cells (GICs), also called glioma stem cells, are responsible for tumor initiation, relapse, and therapeutic resistance. Here, we show that TGF-β inhibitors, currently under clinical development, target the GIC compartment in human glioblastoma (GBM) patients. Using patient-derived specimens, we have determined the gene responses to TGF-β inhibition, which include inhibitors of DNA-binding protein (Id)-1 and -3 transcription factors. We have identified a cell population enriched for GICs that expresses high levels of CD44 and Id1 and tend to be located in a perivascular niche. The inhibition of the TGF-β pathway decreases the CD44 high /Id1 high GIC population through the repression of Id1 and Id3 levels, therefore inhibiting the capacity of cells to initiate tumors. High CD44 and Id1 levels confer poor prognosis in GBM patients. © 2010 Elsevier Inc.
AB - Glioma-initiating cells (GICs), also called glioma stem cells, are responsible for tumor initiation, relapse, and therapeutic resistance. Here, we show that TGF-β inhibitors, currently under clinical development, target the GIC compartment in human glioblastoma (GBM) patients. Using patient-derived specimens, we have determined the gene responses to TGF-β inhibition, which include inhibitors of DNA-binding protein (Id)-1 and -3 transcription factors. We have identified a cell population enriched for GICs that expresses high levels of CD44 and Id1 and tend to be located in a perivascular niche. The inhibition of the TGF-β pathway decreases the CD44 high /Id1 high GIC population through the repression of Id1 and Id3 levels, therefore inhibiting the capacity of cells to initiate tumors. High CD44 and Id1 levels confer poor prognosis in GBM patients. © 2010 Elsevier Inc.
U2 - 10.1016/j.ccr.2010.10.023
DO - 10.1016/j.ccr.2010.10.023
M3 - Article
VL - 18
SP - 655
EP - 668
JO - Cancer Cell
JF - Cancer Cell
SN - 1535-6108
IS - 6
ER -